We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




NIV Test to Diagnose and Monitor Vascular Complications in Diabetes

By LabMedica International staff writers
Posted on 07 Oct 2019
Print article
Image: A ball-and-stick model of the 5-hydroxymethylcytosine (5hmC) molecule (Photo courtesy of Wikimedia Commons).
Image: A ball-and-stick model of the 5-hydroxymethylcytosine (5hmC) molecule (Photo courtesy of Wikimedia Commons).
By applying a sensitive test for analysis of DNA taken from patients with Type II diabetes, researchers were able to diagnose and monitor the presence and severity of diabetic vascular complications such as heart disease, atherosclerosis, and kidney failure.

About two-thirds of the 424 million diabetic patients worldwide die from vascular complications. Therefore, a clinically convenient, noninvasive approach for monitoring the development of these complications would improve the overall life quality of patients with Type II diabetes and help reduce healthcare burden through preventive interventions.

Investigators at Northwestern University (Chicago, IL, USA) had demonstrated previously that 5-hydroxymethylcytosine (5hmC), a relative stable intermediate product of active DNA demethylation, played a critical role in gene expression regulation and was also regarded as a novel epigenetic biomarker for cancer diagnosis and prognosis. They had invented TAB-seq, a method that could map 5hmC at base-resolution genome-wide, as well as hmC-Seal, a method that covalently labeled 5hmC for its detection. Furthermore, they introduced a sensitive and robust 5hmC sequencing approach which allowed genome-wide profiling of 5hmC using a limited amount of genomic DNA that could be readily isolated from only about 1,000 cells (nano-hmC-Seal).

The investigators applied this method to analyze three to five milliliter blood samples obtained from 62 diabetic patients (12 patients without vascular complications, 34 patients with a singular vascular complication, and 16 with multiple vascular complications).

Results revealed statistically significant changes in 5hmC markers associated with Type II diabetes-related macrovascular/microvascular complications, involving genes and pathways relevant to vascular biology and diabetes, including insulin resistance and inflammation. A 16-gene 5hmC marker panel accurately distinguished patients with vascular complications from those without, outperforming conventional clinical variables such as urinary albumin. In addition, a separate 13-gene 5hmC marker panel could distinguish patients with single complications from those with multiple complications, showing superiority over conventional clinical variables.

"We are very excited to apply our earlier findings in cancer patients to diabetic patients," said contributing author Dr. Wei Zhang, associate professor of cancer epidemiology and prevention at Northwestern University. "This discovery is going to revolutionize how quickly and non-invasively we can identify potentially fatal complications in the hundreds of millions of diabetic patients worldwide."

The work was published in the October 1, 2019, online edition of the journal Clinical Chemistry.

Related Links:
Northwestern University

Gold Supplier
Thrombin Generation System
ST Genesia
New
Silver Supplier
Automated Nucleic Acid Extractor
NE48/96
New
Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
New
Gold Supplier
Liquid Handling Workstation
AdvanSure E3 SYSTEM

Print article

Channels

Pathology

view channel

Certest Offers Real-Time PCR Assays for Fast Detection of MDR Bacterial Infections

CerTest Biotec (Zaragoza, Spain) has joined the fight against multidrug resistant strains (MDR) bacterial infections by developing real-time PCR assays for the fast detection of genes or punctual mutations that confer resistance to antibiotics from both Gram-positive and Gram-negative pathogens. Resistance to antibiotics... Read more

Industry

view channel
Illustration

Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.